Compare ADPT & SHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | SHC |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.2B |
| IPO Year | 2019 | 2020 |
| Metric | ADPT | SHC |
|---|---|---|
| Price | $28.14 | $18.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $30.21 | $22.61 |
| AVG Volume (30 Days) | ★ 2.0M | 1.9M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.89 | ★ 68.75 |
| EPS | N/A | ★ 0.28 |
| Revenue | $276,976,000.00 | ★ $1,163,617,000.00 |
| Revenue This Year | $5.03 | $7.16 |
| Revenue Next Year | $22.97 | $5.90 |
| P/E Ratio | ★ N/A | $66.66 |
| Revenue Growth | ★ 54.77 | 5.74 |
| 52 Week Low | $12.00 | $13.09 |
| 52 Week High | $30.74 | $19.85 |
| Indicator | ADPT | SHC |
|---|---|---|
| Relative Strength Index (RSI) | 59.54 | 57.87 |
| Support Level | $23.73 | $18.19 |
| Resistance Level | $30.35 | $19.72 |
| Average True Range (ATR) | 1.47 | 0.44 |
| MACD | 0.32 | 0.11 |
| Stochastic Oscillator | 83.27 | 81.03 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.